Sign in to fuzzto save your conversations, follow your research and come back anytime.
Zota Healthcare
ZOTA
NSE
NSESectorHealthcare
1,101.20
Loading chart…
NSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Rapid retail expansion drives top-line growth, but surging operational costs and heavy borrowing pressure profitability.
Davaindia store count grows from 1,582 in Q4 2024-25 to 2,825 in Q1 FY27, validating aggressive retail network expansion.
Consolidated EBITDA falls from ₹795.7 Cr in Q2 FY26 to -₹2,781.49 Cr in Q1 FY27, warning of severe core profitability erosion.
Consolidated revenue expands from ₹9,727.5 Cr in Q4 2024-25 to ₹17,360.23 Cr in Q1 FY27, driven by strong top-line momentum.
Operational expenses surge from ₹4,693.3 Cr in Q4 2024-25 to ₹13,741.83 Cr in Q1 FY27, outpacing revenue growth and compressing margins.
Gross margin improves from 50.8% in Q4 2024-25 to 61.96% in Q1 FY27, confirming strong pricing power and product mix optimization.
Export revenue drops from ₹1,233.7 Cr in Q4 2024-25 to ₹573.51 Cr in Q1 FY27, signaling weakening international demand and margin pressure.
COCO footfall climbs from 19.0 in Q4 2024-25 to 44.2 in Q1 FY27, reflecting robust customer traffic growth across company-owned outlets.
Current borrowings spike from ₹61.0 Cr in Q4 2024-25 to ₹2,235.56 Cr in Q4 FY26, indicating heavy reliance on short-term funding for expansion.
Davaindia revenue contribution rises from 64% in Q4 2024-25 to 83% in Q1 FY27, cementing the retail segment as the primary growth engine.
Everyday Herbal Group EBITDA margin collapses from 27% in Q1 FY26 to -35.17% in Q1 FY27, reflecting deepening operational losses in the segment.
